OBJECTIVE: This case-based review aims to describe the clinical findings, treatment, and outcome of an HIV/AIDS patient with psoriatic arthritis (PsA) who received four anti-TNF agents and review case reports concerning this rare clinical association.

CASE REPORT: A 51-year-old man was diagnosed in 2008 with psoriatic arthritis. He was initially treated

with methotrexate 17.5 mg/week and had a partial response. Next, he received various anti-TNF agents,

with inadequate or no response, including etanercept, infliximab, adalimumab, and finally golimumab,

when he experienced good response. He received the HIV diagnosis in 1998, initially treated with lamivudine,

zidovudine, and efavirenz. Other comorbidities were systemic hypertension, diabetes mellitus

type 2, dyslipidemia, and acute myocardial infarct in 2016 treated with a revascularization surgery, heart

arrhythmia, and depression. He is currently treated with golimumab, methotrexate, antiretroviral agents

(lamivudine, zidovudine, and dolutegravir), vitamin D, and adequate PsA control.

CONCLUSIONS: The present article describes a unique case of an HIV patient who received four different

TNF blockers to obtain clinical control of PsA. It seems that TNF-α inhibitors are a viable option for psoriasis/

PsA patients with HIV without advanced disease.